The Pentagon has reinstated mandatory testosterone-deficiency screening for U.S. service members aged 30 and older, effective immediately, following a brief pause in early September to update medical guidance.
The Defense Health Agency (DHA) issued comprehensive clinical guidance on September 17, establishing uniform screening and treatment pathways across military departments. Screening is now tied to annual periodic health assessments for troops 30 and older, while those younger than 30 may still request it. Treatment, if recommended, remains voluntary.
The guidance, originally published on September 2, was temporarily rescinded to allow for updates before being reinstated. The original document required testosterone-deficiency screening for male active-duty and reserve members 30 and older during yearly health assessments. A standardized questionnaire assessed symptoms such as diminished physical performance, “brain fog,” reduced endurance, or decreased sexual health. A “yes” response to any item prompted further diagnostic evaluation.
Female service members of all ages are also subject to annual screening for hormonal dysregulation. The guidance evaluates symptoms including fatigue, musculoskeletal pain, or menstrual changes, with potential evaluations for relative energy deficiency in sports. Women 35 and older may additionally be checked for perimenopause and menopause-related symptoms, with allowances for modified training or physical duty limits based on severity.
Pentagon spokesman Sean Parnell stated that the updated guidance ensures compliance and uniformity across the DHA enterprise. The decision follows an earlier announcement by Defense Secretary Pete Hegseth in July, who had promoted testosterone use to enhance military readiness. The policy’s reinstatement comes amid ongoing discussions about its necessity and potential health implications.